On April 24, 2026, the French government announced a new legislative framework aimed at strengthening the National Agency for the Safety of Medicines and Health Products (ANSM) and reinforcing health sovereignty. The law, passed by the National Assembly, grants the ANSM expanded powers to monitor and regulate the pharmaceutical supply chain, including the ability to impose production quotas and stockpile critical drugs.
The legislation responds to recent shortages of essential medicines, such as antibiotics and painkillers, which have affected patients across France. According to the Ministry of Health, the law mandates that pharmaceutical companies report potential shortages earlier and maintain minimum stock levels. It also establishes a national observatory to track drug availability and production capacity.
Health Minister Catherine Vautrin stated, 'This law is a crucial step to protect French patients and ensure our health system is resilient against future crises.' The measure is part of a broader European effort to reduce dependency on non-EU drug manufacturing, particularly from Asia.
Industry groups have expressed support but warned that implementation will require significant investment in domestic production facilities. The law is expected to take full effect by 2027, with interim measures starting in late 2026.
